WeVote
Log In

Bill

Bill

A 7112

Authorizes and directs the department of health to conduct a study on drugs prescribed for school age children with ADD and ADHD

2025 Regular Session Introduced by Scott Bendett and 4 co-sponsors

Bill A 7112 directs New York's Health Department to study medications for school-age children with ADD/ADHD, aiming to improve treatment and inform future policies.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 7112

Summary of Bill A 7112

Bill Overview

  • Bill Number: A 7112
  • Title: Authorizes and directs the Department of Health to conduct a study on drugs prescribed for school-age children with ADD and ADHD
  • Status: Referred to Health Committee
  • Introduced On: March 20, 2025
  • Classification: Bill

Purpose and Intent

The primary purpose of Bill A 7112 is to authorize the New York State Department of Health to conduct a comprehensive study focused on the medications prescribed to school-age children diagnosed with Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD). The intent of this study is to gather data that can inform future policies and practices regarding the treatment of these conditions in children.

Key Provisions

  • Study Authorization: The bill mandates the Department of Health to initiate a study that will analyze:
    • The types of medications commonly prescribed for ADD and ADHD.
    • The effectiveness of these medications in managing symptoms.
    • Any potential side effects or long-term impacts associated with their use in children.
  • Data Collection: The study will involve collecting data from healthcare providers, schools, and parents to ensure a comprehensive understanding of the prescribing practices and outcomes.
  • Reporting Requirements: The Department of Health will be required to compile the findings of the study into a report, which will be submitted to the legislature. This report is expected to include recommendations based on the findings.

Who Would Be Affected

  • Children: The primary group affected by this bill includes school-age children diagnosed with ADD and ADHD who are prescribed medication as part of their treatment.
  • Parents and Guardians: Families of children with these diagnoses will benefit from the insights gained from the study, potentially leading to better-informed treatment options.
  • Healthcare Providers: Physicians and mental health professionals who prescribe medications for ADD and ADHD will be impacted by any new guidelines or recommendations that emerge from the study.
  • Educational Institutions: Schools may also be affected, as the findings could influence how they support students with ADD and ADHD.

Procedural Aspects

  • Current Status: As of the introduction date, the bill has been referred to the Health Committee for further consideration.
  • Related Legislation: Bill A 7112 is related to several prior-session bills (A 6785, A 6390, A 3439, A 4527, A 1969) and has a companion bill in the Senate (S 3891), indicating ongoing legislative interest in the topic of ADD and ADHD treatment.

Conclusion

Bill A 7112 represents a significant step towards understanding and improving the treatment of ADD and ADHD in school-age children. By conducting a thorough study on prescribed medications, the bill aims to enhance the quality of care and ensure that children receive effective and safe treatment options. The outcomes of this study could lead to important policy changes and better health outcomes for affected children and their families.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.